TH17GLOBAL COMPANY LIMITED
Th17 Global Co. Ltd. is a newly incorporated company providing Natural Cancer Care. Its parent company, Asian Phytoceuticals Public Co. Ltd., has been listed on Thailand’s Market for Alternative Investments since November 2011. The products in both companies are the result of multi-disciplinary research undertaken at the Thai Mangosteen Research and Development Center in Thailand.
The team’s research has been driven and expanded in part by recent important discoveries from the USA. In November 2009, Dr. Chen Dong from the M. D. Anderson Cancer Research Center at the University of Texas discovered that the white blood cell, Th17, is effective in preventing and curing cancer. His plan was to clone the Th17 and use it for cancer treatment.
In 2010, Dr. Carl June of the Abramson Cancer Center, University of Pennsylvania, was able to increase dramatically the number of Th17 cells and used them to treat three patients suffering from leukemia. Two of the three patients were cured but one only partially recovered. Prior to that, several similar attempts to use Th17 cells had failed because of side effects, and death resulted in one such case.
At present, we can confidently say that Th17 can inhibit and kill cancer cells, but using it as a safe and effective treatment needs further improvement and testing.
In Thailand, Th17 has played a role in improving the quality of life of cancer patients since 2008, using a proven regimen of a proprietary formula of Mangosteen juice and capsules. This has resulted from joint research and development efforts by the multi-disciplinary research team of the Asian Phytoceuticals Public Co. Ltd (APCO), with the support of many organisations from both the public and private sectors. Through its research, the team has recorded the world’s first success in innovatively utilizing a natural substance formula to increase Th17 levels to improve the quality of life for cancer patients.